ClinicalTrials.gg
CompletedNCT02559713Updated Jan 8, 2021Results posted

Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease

A Phase 4 interventional study of Vedolizumab in Colitis, Ulcerative and Crohn's Disease, sponsored by Takeda. Completed at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-08.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
34th of 38
11 · median 110
Started
2017
with 7 others
Phase 4
15 of 38
2 open now
Registered
8th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 34th largest by enrollment, is one of 8 that started in 2017, is one of 15 in phase 4, and was the 8th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to assess the concentration of vedolizumab in breast milk of lactating women with active ulcerative colitis (UC) or Crohn's disease (CD) who are receiving vedolizumab therapeutically.

Read the detailed description

The drug being tested in this study is called vedolizumab. This post-marketing milk-only lactation study will assess concentrations of vedolizumab in breast milk of lactating women with active UC or CD who are receiving vedolizumab therapeutically.

The study will enroll approximately 12 participants. All participants who received an established vedolizumab maintenance regimen or has completed induction therapy for the treatment of active UC or CD.

30-minute IV infusion of 300 mg vedolizumab. This multi-center trial will be conducted in the United States. The overall time to participate in this study is 3 months. Participants will make visits to clinic, study site or HCP office at Screening, Check-in (Day -1). Visits on Days 4, 8, 15, or 29 may be completed at the participant's home setting in the presence of a qualified nurse, or at a clinic, study site or other HCP office. The study exit/follow-up safety assessment will occur on Day 57(±3).

03

Conditions studied

  • Colitis, Ulcerative
  • Crohn's Disease

Keywords

  • Lactation
  • Lactating Women
  • Vedolizumab
  • Colitis Ulcerative
  • Crohn's Disease
  • Crohn's
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is capable of understanding and complying with protocol requirements.
  2. Signs and dates as written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Is female and at least 18 years of age at the time of informed consent.
  4. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent and throughout the duration of the study.
  5. Is on established vedolizumab maintenance therapy and received at least 1 dose of 300 mg of vedolizumab IV postpartum or has completed vedolizumab induction therapy (300 mg of vedolizumab IV at Week 0, Week 2, and Week 6), which has been commenced by the participant's treating physician for the treatment of active UC or CD prior to enrolling in this study.
  6. Has delivered a single, normal term infant (at least 37 weeks' gestation) that is, a mother-infant pair is required.
  7. Is at least 5 weeks postpartum by Day 1.
  8. Lactation is well established, and the mother is exclusively breast feeding her infant (or not providing more than 1 supplemental bottle of formula/day) when enrolled in the study.
  9. Participant has independently decided to be treated with vedolizumab or to breastfeed prior to providing consent to participate in this study.
  10. Plans to continue breastfeeding at least throughout the duration of this study.
  11. Agrees to use only the emollient or nipple cream recommended by the investigator for use during the sampling period.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound or approved biologic or biosimilar agent, except for vedolizumab within 60 days prior to enrollment in the study.
  2. Within 30 days prior to enrollment, the participant has received any of the following for the treatment of underlying disease:

    • Nonbiologic therapies [example (eg), cyclosporine], other than those listed in the protocol.
    • An approved nonbiologic therapy in an investigational protocol.
  3. Has received any within 30 days prior to vedolizumab administration.
  4. Has infection (eg, pneumonia, pyelonephritis) or chronic infection within 30 days prior to enrollment.
  5. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  6. Has evidence of unstable or uncontrolled, clinically significant cardiovascular, central nervous system, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic or other medical disorder, including serious allergy, asthma, hypoxemia, hypertension, seizures or allergic skin rash that, in the opinion of the investigator, would confound the study results or compromise participant safety. Additionally, if there is any finding in the participant's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking vedolizumab, or a similar drug that might interfere with the conduct of the study.
  7. Had any surgical procedure requiring general anesthesia within 30 days prior to enrollment or is planning to undergo major surgery during the study period.
  8. Has any history of , except for the following: (a) adequately treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to enrollment; and (c) history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to enrollment. Participants with remote history of malignancy (eg, greater than (>) 10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to enrollment.
  9. Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
  10. Has a positive progressive multifocal leukoencephalopathy subjective symptom checklist at screening.
  11. Has a current or recent history (within 1 year prior to enrollment) of alcohol dependence or illicit drug use.
  12. Has active psychiatric problems that, in the investigator's opinion, may interfere with compliance with the study procedures.
  13. Is unable to participate in all the study visits or comply with study procedures.
  14. Has history of breast implants, breast augmentation, or breast reduction surgery.
  15. Has a prior history of difficulty establishing lactation.
  16. Has taken any excluded medication, supplements, or food products during the time periods listed in the Excluded Medications and Dietary Products table.
  17. Has donated or lost 450 milliliters or more of her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days prior to Day 1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Vedolizumab 300 milligram (mg)

    Vedolizumab 300 mg, IV infusion over 30-minutes, single dose on Day 1.

    Drug: Vedolizumab

Interventions

  • Vedolizumab IV infusion

    Also known as: Entyvio, MLN0002

06

What researchers measure

Primary outcomes

  1. Concentration of Vedolizumab in Breast Milk at Predose on Day 1

    Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by enzyme-linked immunosorbent assay (ELISA). Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

    Time frame: Day 1 (60 minutes prior to the start of infusion)

  2. Concentration of Vedolizumab in Breast Milk at 1 Hour After the End of Infusion on Day 1

    Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

    Time frame: Day 1 (approximately 60 minutes after the end of infusion)

  3. Concentration of Vedolizumab in Breast Milk on Day 4

    Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants unable to return to the clinic could have their milk samples collected at home by a qualified and trained homecare nurse. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

    Time frame: Day 4

  4. Concentration of Vedolizumab in Breast Milk on Day 8

    Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants unable to return to the clinic could have their milk samples collected at home by a qualified and trained homecare nurse. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

    Time frame: Day 8

  5. Concentration of Vedolizumab in Breast Milk on Day 15

    Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants unable to return to the clinic could have their milk samples collected at home by a qualified and trained homecare nurse. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

    Time frame: Day 15

  6. Concentration of Vedolizumab in Breast Milk on Day 29

    Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants unable to return to the clinic could have their milk samples collected at home by a qualified and trained homecare nurse. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

    Time frame: Day 29

  7. Concentration of Vedolizumab in Breast Milk on Day 57

    Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk in participants with analysis of vedolizumab concentration from the pooled milk sample was done by ELISA.

    Time frame: Day 57

07

Results

Posted Mar 4, 2020

Participant flow

Participants took part in the study at 4 investigative sites in the United States from 29 November 2017 to 22 February 2019.

Participant flow — Overall Study
MilestoneVedolizumab 300 mg
Started11
Safety set11
Pharmacokinetic set11
Completed10
Not completed1
Withdrew: Pretreatment event/ adverse event1

Outcome measures

PrimaryConcentration of Vedolizumab in Breast Milk at Predose on Day 1

Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by enzyme-linked immunosorbent assay (ELISA). Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

Time frame:
Day 1 (60 minutes prior to the start of infusion)
Reported as:
Mean · ug/mL
Concentration of Vedolizumab in Breast Milk at Predose on Day 1
ug/mLVedolizumab 300 mg
Q4W0.1350 ± NA
Q6W0 ± NA
Q8W0.03161 ± 0.024327
PrimaryConcentration of Vedolizumab in Breast Milk at 1 Hour After the End of Infusion on Day 1

Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

Time frame:
Day 1 (approximately 60 minutes after the end of infusion)
Reported as:
Mean · ug/mL
Concentration of Vedolizumab in Breast Milk at 1 Hour After the End of Infusion on Day 1
ug/mLVedolizumab 300 mg
Q4W0.1490 ± NA
Q6W0 ± NA
Q8W0.03756 ± 0.025572
PrimaryConcentration of Vedolizumab in Breast Milk on Day 4

Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants unable to return to the clinic could have their milk samples collected at home by a qualified and trained homecare nurse. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

Time frame:
Day 4
Reported as:
Mean · ug/mL
Concentration of Vedolizumab in Breast Milk on Day 4
ug/mLVedolizumab 300 mg
Q4W0.3050 ± NA
Q6W0.1650 ± NA
Q8W0.2634 ± 0.14840
PrimaryConcentration of Vedolizumab in Breast Milk on Day 8

Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants unable to return to the clinic could have their milk samples collected at home by a qualified and trained homecare nurse. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

Time frame:
Day 8
Reported as:
Mean · ug/mL
Concentration of Vedolizumab in Breast Milk on Day 8
ug/mLVedolizumab 300 mg
Q4W0.3050 ± NA
Q6W0.1410 ± NA
Q8W0.2113 ± 0.10299
PrimaryConcentration of Vedolizumab in Breast Milk on Day 15

Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants unable to return to the clinic could have their milk samples collected at home by a qualified and trained homecare nurse. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

Time frame:
Day 15
Reported as:
Mean · ug/mL
Concentration of Vedolizumab in Breast Milk on Day 15
ug/mLVedolizumab 300 mg
Q4W0.2280 ± NA
Q6W0.1270 ± NA
Q8W0.1708 ± 0.069017
PrimaryConcentration of Vedolizumab in Breast Milk on Day 29

Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk. Analysis of vedolizumab concentration from the pooled milk sample was done by ELISA. Participants unable to return to the clinic could have their milk samples collected at home by a qualified and trained homecare nurse. Participants were categorized as per their past vedolizumab regimens, received prior to Day 1: vedolizumab every 4 weeks (Q4W), vedolizumab every 6 weeks (Q6W), vedolizumab every 8 weeks (Q8W).

Time frame:
Day 29
Reported as:
Mean · ug/mL
Concentration of Vedolizumab in Breast Milk on Day 29
ug/mLVedolizumab 300 mg
Q4W0.1560 ± NA
Q6W0.06860 ± NA
Q8W0.1039 ± 0.040445
PrimaryConcentration of Vedolizumab in Breast Milk on Day 57

Milk from each breast was completely emptied using an electric milk pump at the specified time point for the determination of vedolizumab concentrations in the milk in participants with analysis of vedolizumab concentration from the pooled milk sample was done by ELISA.

Time frame:
Day 57
Reported as:
Mean · ug/mL
Concentration of Vedolizumab in Breast Milk on Day 57
ug/mLVedolizumab 300 mg
Concentration of Vedolizumab in Breast Milk on Day 570.04673 ± 0.020966

Adverse events

Collected over First dose of study drug in this study to study exit (Up to Day 57). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vedolizumab 300 mg0/11 (0%)1/11 (9.1%)3/11 (27.3%)
Most frequent serious events
Most frequent serious events
EventVedolizumab 300 mg
Colitis ulcerativeGastrointestinal disorders1/11
Most frequent other events
Most frequent other events
EventVedolizumab 300 mg
Crohn's diseaseGastrointestinal disorders1/11
Gastrointestinal motility disorderGastrointestinal disorders1/11
ParonychiaInfections and infestations1/11
Viral infectionInfections and infestations1/11

Baseline characteristics

Safety Set included all participants who received any amount of vedolizumab in this study.

Age, Continuous
Age, Continuous(years)Vedolizumab 300 mg
Mean31.8 ± 3.71
Sex: Female, Male
Sex: Female, Male(Participants)Vedolizumab 300 mg
Female11
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vedolizumab 300 mg
Hispanic or Latino0
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vedolizumab 300 mg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Vedolizumab 300 mg
United States11
Height
Height(centimeter (cm))Vedolizumab 300 mg
Mean158.9 ± 7.12
Weight
Weight(kilograms (kg))Vedolizumab 300 mg
Mean62.72 ± 15.924
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vedolizumab 300 mg
Mean24.78 ± 5.534

6 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Feinberg School of Medicine Northwestern University
    Chicago, Illinois 60637, United States
  • Carle Foundation Hospital
    Urbana, Illinois 61801, United States
  • Atlantic Health System
    Morristown, New Jersey 07960, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1150, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Sun W, Fennimore B, Beaulieu DB, Arsenescu R, Stein AC, Chen J, Lin T, McKnight S, Kadali H, Rosario M, Lirio RA. Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease. Clin Pharmacokinet. 2021 Jun;60(6):811-818. doi: 10.1007/s40262-021-00985-4. Epub 2021 Feb 5. PubMed 33544318 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Feb 2019, 14 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 63 phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 63. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2015
First posted
Sep 24, 2015
StartActual
Nov 29, 2017
Primary completionActual
Feb 22, 2019
CompletionActual
Feb 22, 2019
Results first posted
Mar 4, 2020
Last update
Jan 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02559713
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 24, 2015
Start date
Nov 29, 2017
Primary completion
Feb 22, 2019
Completion
Feb 22, 2019
Results posted
Mar 4, 2020
Last update
Jan 8, 2021

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion